title: Occurrence of multiple myeloma 13 years after Hodgkin's disease: chance or consequence?
authors.forename: Eva-Susanne
authors.initials: ES
authors.lastname: Strobel
authors.forename: Kris
authors.initials: K
authors.lastname: Bauchmüller
authors.forename: Annette
authors.initials: A
authors.lastname: Schmitt-Gräff
authors.forename: Monika
authors.initials: M
authors.lastname: Engelhardt
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D001859:Bone Neoplasms / Q000188:drug therapy*; D002330:Carmustine / Q000008:administration & dosage; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D005260:Female; D006689:Hodgkin Disease / Q000628:therapy; D006801:Humans; D008558:Melphalan / Q000008:administration & dosage; D009101:Multiple Myeloma / Q000188:drug therapy*; D016609:Neoplasms, Second Primary / Q000188:drug therapy*; D011241:Prednisone / Q000008:administration & dosage; D011344:Procarbazine / Q000008:administration & dosage; D014750:Vincristine / Q000008:administration & dosage; D014916:Whole-Body Irradiation
chemical_list: D011344:Procarbazine; D014750:Vincristine; D003520:Cyclophosphamide; D008558:Melphalan; D002330:Carmustine; D011241:Prednisone